Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Katherine Sue Robinson"'
Autor:
Bryn Pressnail, Ari M. Vanderwalde, Nancy L. Bartlett, Mitchell R. Smith, Paul G. Montgomery, Jonathan W. Friedberg, Ann S. LaCasce, Tricia Ellis, Anthony J. Dodds, Peter Martin, Jeff Szer, Richard van der Jagt, Saurabh Rajguru, Michael D. Williams, Zhengming Chen, Michael Bar, Kristen N. Ganjoo, Katherine Sue Robinson, Fernando Cabanillas, John P. Leonard, Robin Joyce, Jordan A. Herst, Bruce D. Cheson, Bernard Lemieux
Publikováno v:
British Journal of Haematology. 178:250-256
Summary Despite the long history of bendamustine as treatment for indolent non-Hodgkin lymphoma, long-term efficacy and toxicity data are minimal. We reviewed long-term data from three clinical trials to characterize the toxicity and efficacy of pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ade34713a1ccbdc7b6fa11c2952593d1
https://doi.org/10.1111/bjh.14667
https://doi.org/10.1111/bjh.14667
Autor:
David Lillicrap, L. Li, Katherine Sue Robinson, Angie Tuttle, Paula D. James, Fred G. Pluthero, Hilary Christensen, Walter H. A. Kahr, M. Bowman, Lara J. Casey
Publikováno v:
Journal of thrombosis and haemostasis : JTH. 15(7)
Essentials von Willebrand factor (VWF) is synthesized in endothelial cells and platelet precursors. Type 3 patients with Pro2808Leufs*24 have lower bleeding scores than other type 3s. The Pro2808Leufs*24 variant was examined in patient platelets and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64c4db903b220e4f7fbe71f556e64bbf
https://pubmed.ncbi.nlm.nih.gov/28453889
https://pubmed.ncbi.nlm.nih.gov/28453889
Autor:
Victor S. Blanchette, Katherine Sue Robinson, Ming Yang, John K. Wu, Alfonso Iorio, Adrienne Lee, Robert J. Klaassen, Haowei Linda Sun, Shannon Jackson, Man-Chiu Poon, Michelle Sholzberg
Publikováno v:
Blood. 132:4813-4813
Introduction: Recombinant Factors VIII Fc (rFVIIIFc) and IX Fc (rFIXFc) fusion proteins are extended half-life (EHL) factor products approved in Canada in 2014 and became available through the Canadian Blood Services in January 2016. Real-world produ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a2bab2aafd3eee3bb8431c66f3e299ff
https://doi.org/10.1182/blood-2018-99-113858
https://doi.org/10.1182/blood-2018-99-113858
Autor:
Jonathan W. Friedberg, Ann S. LaCasce, Peter Martin, Anthony J. Dodds, Mitchell R. Smith, Michael Bar, Ari M. Vander Walde, Tricia Ellis, Saurabh Rajguru, Jordan A. Herst, Kristen N. Ganjoo, Richard van der Jagt, Zhengming Chen, Michael E. Williams, Paul G. Montgomery, Bryn Pressnail, Katherine Sue Robinson, Nancy L. Bartlett, Bruce D. Cheson, Fernando Cabanillas, Bernard Lemieux, Robin Joyce, Jeff Szer, John P. Leonard
Publikováno v:
Blood. 126:3961-3961
Background Given the widespread use of bendamustine, data on long-term outcomes are essential for patients and clinicians to understand potential risks and benefits of therapy. Despite a long history as treatment for indolent non-Hodgkin lymphoma (iN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::203eb06ed977e5f05df72721680078dc
https://doi.org/10.1182/blood.v126.23.3961.3961
https://doi.org/10.1182/blood.v126.23.3961.3961
Autor:
David Lillicrap, Fred G. Pluthero, Walter H. A. Kahr, Victor S. Blanchette, Katherine Sue Robinson, Paula D. James
Publikováno v:
Blood. 114:3059-3059
Abstract 3059 Poster Board II-1035 Type 3 von Willebrand disease (VWD) is characterized by the virtual absence of von Willebrand factor (VWF) in plasma. Affected individuals are usually either homozygous or compound heterozygous for mutations that ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2669cd526c50c65967844202e3ca793c
https://doi.org/10.1182/blood.v114.22.3059.3059
https://doi.org/10.1182/blood.v114.22.3059.3059
Autor:
Karim Abou-Nassar, Michael J. Kovacs, Mark Blostein, Susan R. Kahn, Ramsay Tim, Katherine Sue Robinson, Steve Doucette, Philip S. Wells, Marc A. Rodger, Susan Solymoss, Evelyne Rey
Publikováno v:
Blood. 108:874-874
Background: Low-molecular weight heparin (LMWH) is increasingly being used for prophylaxis of venous thromboembolism (VTE) and prevention of pregnancy associated morbidity in pregnant women with thrombophilia. Objective: We sought to determine if the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0cc014e4dbcad341e174b4bd877d9b3a
https://doi.org/10.1182/blood.v108.11.874.874
https://doi.org/10.1182/blood.v108.11.874.874
Autor:
Jordan A. Herst, Philip Cohen, Michael E. Williams, Anil Tulpule, Jennifer W. Oliver, Katherine Sue Robinson, Lee S. Schwartzberg, Richard van der Jagt, Bruce D. Cheson, Bernard Lemieux
Publikováno v:
Blood. 108:2710-2710
Objective: The objective of this study was to evaluate the efficacy and safety of bendamustine HCl (TREANDA®) in combination with rituximab in patients with relapsed non-Hodgkin’s lymphoma (NHL). Background: Bendamustine is a novel hybrid, alkylat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c055d2ef53fd69c0072bfffd3e09e7d
https://doi.org/10.1182/blood.v108.11.2710.2710
https://doi.org/10.1182/blood.v108.11.2710.2710
Autor:
Alberto Bessudo, Philip R. Cohen, Jennifer Oliver, Lee S. Schwartzberg, Jordan A. Herst, R. H. Van der Jagt, Katherine Sue Robinson, Bernard Lemieux, Michael E. Williams, Anil Tulpule
Publikováno v:
Journal of Clinical Oncology. 24:7528-7528
7528 Background: Bendamustine HCl, a novel alkylating hybrid agent, has single-agent activity in multiple hematologic and solid tumors. In vitro data have demonstrated the multifunctional mechanisms of bendamustine by which cell death occurs via both
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::827112df3be059ac0c16be2fa98519be
https://doi.org/10.1200/jco.2006.24.18_suppl.7528
https://doi.org/10.1200/jco.2006.24.18_suppl.7528
Autor:
Robert Marcus, João Raposo, Andrew Belch, Katherine Sue Robinson, John Catalano, Philippe Solal-Celigny, Fritz Offner, David Cunningham, Paul Smith, Jan Walewski, Kevin Imrie, Antonio Rueda
Publikováno v:
Blood. 106:350-350
Design/Methods: We recently demonstrated in a phase III trial that the addition of rituximab to each of 8 cycles of CVP (R-CVP) chemotherapy significantly improves the clinical outcome of previously untreated patients with stage III/IV CD20 positive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86cf6a204a94cac46f6cb64e53e29b00
https://doi.org/10.1182/blood.v106.11.350.350
https://doi.org/10.1182/blood.v106.11.350.350
Autor:
Philip Cohen, Ely Benaim, Michael E. Williams, Alberto Bessudo, Lee S. Schwartzberg, Anil Tulpule, Katherine Sue Robinson, Robin Joyce, Bernard Lemieux, Jennifer Oliver, Jordan A. Herst, Richard van der Jagt
Publikováno v:
Blood. 106:923-923
Background: Bendamustine hydrochloride (SDX-105; TreandaTM) is a multifunctional, alkylating agent with a purine-like ring system and novel mechanisms of action that exhibits impressive single-agent activity in multiple hematologic and solid tumors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10a35b226dffe228c06d52fe8f7c486a
https://doi.org/10.1182/blood.v106.11.923.923
https://doi.org/10.1182/blood.v106.11.923.923